100% Tariff on Pharmaceutical Imports Coming July 31
The administration announced a Section 232 tariff of 100% on imported patented pharmaceuticals and active pharmaceutical ingredients (APIs), effective July 31, 2026.
If you import supplements, vitamins, branded drugs, or products containing patented active ingredients, you have less than 4 months to prepare.
What's Happening
- 100% tariff on patented pharmaceutical products and active ingredients
- Effective date: July 31, 2026
- Escape hatches: Companies can negotiate down to 0% by signing onshoring + MFN pricing agreements, or 20% with onshoring commitments alone
- EU, Japan, Korea, Switzerland: Reduced rate of 15% (under bilateral agreements)
- Generic drugs and biosimilars: Exempt for now
Who's Affected
This goes beyond Big Pharma. Small importers affected include:
- Supplement companies importing patented ingredients (certain vitamins, amino acids, botanical extracts with patent protection)
- Compounding pharmacies importing active ingredients from India, China, or Europe
- Pet supplement brands importing patented compounds
- Health food companies importing specialty ingredients
- Contract manufacturers who source APIs overseas
Roughly 80% of active pharmaceutical ingredients used in US drugs are manufactured overseas, primarily in China and India. This tariff targets the entire upstream supply chain.
Dollar Impact
For a supplement company importing $100,000/year in patented active ingredients:
- Current cost: $100,000 + ~5% duty = $105,000
- After July 31: $100,000 + 100% duty = $200,000
- If from EU/Japan/Korea/Switzerland: $100,000 + 15% = $115,000
That's a $95,000 annual increase for a small supplement brand. For many, that's the difference between profitability and shutting down the product line.
What You Should Do
-
Audit your ingredients. Which of your imported ingredients have patent protection? Check with your supplier — if the active compound is patented, it likely falls under this tariff.
-
Check the country of origin. EU, Japan, Korea, and Switzerland get the 15% reduced rate. If your supplier has facilities in these countries, sourcing from there instead of China or India saves you 85 percentage points.
-
Stockpile before July 31. If you can afford to buy ahead, goods that clear customs before July 31 face the current rate, not 100%.
-
Explore generic alternatives. Generics and biosimilars are explicitly exempt. If a non-patented equivalent exists, switching eliminates the tariff entirely.
-
Talk to your broker about reclassification. Some products may be classifiable under HTS codes that fall outside the pharma scope. This requires expert analysis — don't guess.
The Onshoring Play
The 0% rate is available to companies that commit to domestic manufacturing AND agree to Most Favored Nation pricing (matching the lowest price charged globally). The 20% rate requires onshoring only.
For small importers, these commitments aren't realistic — you don't control where your supplier manufactures. But your supplier might be motivated to open US facilities if enough customers push for it.
Source
KPMG Analysis | Foley Hoag Legal Advisory
Monitor your HTS codes and get alerted before rate changes hit. Start with TariffDesk →